Multicancer Early Detection Tests — Keeping a High Bar for Evidence of Benefit

The development of multicancer early detection tests has surged in recent years. When evaluating such tests, it will be important to maintain a high bar for concluding that there is evidence of benefit.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-07, Vol.391 (4), p.292-294
1. Verfasser:	Robbins, Hilary A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged and the FDA Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Breast cancer Cancer Cell-Free Nucleic Acids - blood Cell-Free Nucleic Acids - genetics Design Devices DNA Methylation - genetics Drugs Early Detection of Cancer - economics Early Detection of Cancer - methods Genetics Health Policy Hematology Humans Intervention Mammography Medical Ethics Medical screening Middle Aged Mortality Mutation Neoplasm Staging Neoplasms - blood Neoplasms - diagnosis Neoplasms - genetics Neoplasms - pathology Oncology Oncology General Public Health Public Health General Randomized Controlled Trials as Topic United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The development of multicancer early detection tests has surged in recent years. When evaluating such tests, it will be important to maintain a high bar for concluding that there is evidence of benefit.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMp2400297